Trial Search Results
Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease
Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
Stanford is currently not accepting patients for this trial.
- Procedure: high dose chemotherapy and autologous hematopoietic cell transplant
Inclusion Criteria:- active chronic GvHD
- ANC > 1000/mm^3
- therapeutic cyclosporine
Exclusion Criteria:- uncontrolled systemic infection
- elevated serum creatinine
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study